New research uncovers key factors driving survival and treatment response in patients with HER2-positive breast cancer ...

The combination of toripalimab, nimotuzumab, and chemotherapy showed “promising antitumor activity with acceptable toxicity,” researchers wrote.

For patients with breast cancer, the brain functional network shows a shift toward a more randomized pattern after neoadjuvant chemotherapy (NAC), with progression of chemotherapy leading to expanded ...

Dr. Matthew Galsky discusses the FDA approval of Imfinzi and chemo before and after surgery for muscle-invasive bladder ...

Recent investigation focuses on the effects of BRCA1 and BRCA2 tumor pathogenic variants (tPVs) within the parameters of two ...

Residual cancer after neoadjuvant therapy predicts recurrence years later in men undergoing surgery for high-risk prostate cancer.

Omission of endocrine therapy in estrogen receptor (ER)-low early breast cancer had a significant association with worse ...

During a live event, Matthew Galsky, MD discussed neoadjuvant and adjuvant options for a patient case including nivolumab or ...

Surgery may not be the best next course of treatment for p atients with early-stage breast cancer who had a complete response to neoadjuvant (pre-surgical) chemotherapy and standard radiation ...

The precise use of immunotherapy agents in locally advanced head and neck squamous cell carcinoma has not been clearly ...